Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Mounjaro's sales dip: How cheap generics are redrawing India's GLP-1 market The arrival of cheaper semaglutide alternatives signals that the Indian obesity drug market has moved from a launch-led boom into something more structurally competitive Eli Lilly's Mounjaro posted its first monthly sales drop in India in Marcha Rs 20-crore decline, from roughly Rs 135 crore in February to Rs 114 crorejust days after a clutch of Indian generics entered the country's booming GLP-1 market
References Lillys oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
a meaningful CFU count (1015 billion or more)
The 0.25 mg dose will reach lower peak concentrations compared to higher maintenance doses, but the time course for elimination follows the same pattern
